Jiuyuan Genetic (02566) Announces Share Repurchase Details

Bulletin Express01-20 19:02

According to the Next Day Disclosure Return from Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566), the opening balance as of 19 January 2026 comprised 109,035,385 issued shares (excluding treasury shares) and 61,400 treasury shares. A repurchase of 8,400 shares was conducted on 20 January 2026 at an average price of HKD 9.188571 per share. After the transaction, the company held 109,026,985 issued shares (excluding treasury shares) and 69,800 treasury shares, with total issued shares remaining at 109,096,785.

Repurchase data indicates that on 20 January 2026, 8,400 shares were repurchased on the stock exchange at prices ranging from HKD 9.18 to HKD 9.2 per share, resulting in an aggregate price of approximately HKD 77,183.9964. These repurchased shares are being held as treasury shares.

The repurchase mandate was originally approved on 11 June 2025, authorizing up to 10,909,678 shares for repurchase. To date, 69,800 shares have been repurchased under this mandate, representing about 0.06398% of the number of issued shares on the date the mandate was granted. A moratorium applies until 19 February 2026 for any issuance of new shares or sale or transfer of treasury shares following the share repurchase. The official filing states that the process complied with relevant regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119355972?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-20 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119355972","market":"us","top_or_hot":-1,"title":"Jiuyuan Genetic (02566) Announces Share Repurchase Details","media":"Bulletin Express","content":"<p>According to the Next Day Disclosure Return from Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566), the opening balance as of 19 January 2026 comprised 109,035,385 issued shares (excluding treasury shares) and 61,400 treasury shares. A repurchase of 8,400 shares was conducted on 20 January 2026 at an average price of HKD 9.188571 per share. After the transaction, the company held 109,026,985 issued shares (excluding treasury shares) and 69,800 treasury shares, with total issued shares remaining at 109,096,785.</p>\n<p>Repurchase data indicates that on 20 January 2026, 8,400 shares were repurchased on the stock exchange at prices ranging from HKD 9.18 to HKD 9.2 per share, resulting in an aggregate price of approximately HKD 77,183.9964. These repurchased shares are being held as treasury shares.</p>\n<p>The repurchase mandate was originally approved on 11 June 2025, authorizing up to 10,909,678 shares for repurchase. To date, 69,800 shares have been repurchased under this mandate, representing about 0.06398% of the number of issued shares on the date the mandate was granted. A moratorium applies until 19 February 2026 for any issuance of new shares or sale or transfer of treasury shares following the share repurchase. The official filing states that the process complied with relevant regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiuyuan Genetic (02566) Announces Share Repurchase Details</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiuyuan Genetic (02566) Announces Share Repurchase Details\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-01-20 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to the Next Day Disclosure Return from Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566), the opening balance as of 19 January 2026 comprised 109,035,385 issued shares (excluding treasury shares) and 61,400 treasury shares. A repurchase of 8,400 shares was conducted on 20 January 2026 at an average price of HKD 9.188571 per share. After the transaction, the company held 109,026,985 issued shares (excluding treasury shares) and 69,800 treasury shares, with total issued shares remaining at 109,096,785.</p>\n<p>Repurchase data indicates that on 20 January 2026, 8,400 shares were repurchased on the stock exchange at prices ranging from HKD 9.18 to HKD 9.2 per share, resulting in an aggregate price of approximately HKD 77,183.9964. These repurchased shares are being held as treasury shares.</p>\n<p>The repurchase mandate was originally approved on 11 June 2025, authorizing up to 10,909,678 shares for repurchase. To date, 69,800 shares have been repurchased under this mandate, representing about 0.06398% of the number of issued shares on the date the mandate was granted. A moratorium applies until 19 February 2026 for any issuance of new shares or sale or transfer of treasury shares following the share repurchase. The official filing states that the process complied with relevant regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02566","symbol_name":"九源基因","start_time":0,"source_url":"","article_id":"1119355972","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119355972","pubTimestamp":1768906976,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"According to the Next Day Disclosure Return from Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566), the opening balance as of 19 January 2026 comprised 109,035,385 issued shares (excluding...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02566":"九源基因"},"translate_title":"九原基因(02566)公布购回股份详情","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02566":1},"content_text":"According to the Next Day Disclosure Return from Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566), the opening balance as of 19 January 2026 comprised 109,035,385 issued shares (excluding treasury shares) and 61,400 treasury shares. A repurchase of 8,400 shares was conducted on 20 January 2026 at an average price of HKD 9.188571 per share. After the transaction, the company held 109,026,985 issued shares (excluding treasury shares) and 69,800 treasury shares, with total issued shares remaining at 109,096,785.\nRepurchase data indicates that on 20 January 2026, 8,400 shares were repurchased on the stock exchange at prices ranging from HKD 9.18 to HKD 9.2 per share, resulting in an aggregate price of approximately HKD 77,183.9964. These repurchased shares are being held as treasury shares.\nThe repurchase mandate was originally approved on 11 June 2025, authorizing up to 10,909,678 shares for repurchase. To date, 69,800 shares have been repurchased under this mandate, representing about 0.06398% of the number of issued shares on the date the mandate was granted. A moratorium applies until 19 February 2026 for any issuance of new shares or sale or transfer of treasury shares following the share repurchase. The official filing states that the process complied with relevant regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119355972","isCrawlerRequest":true}